Perrigo Company (PRGO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.50
- Estimate
- $0.36
- Surprise
- +40.9%
- Revenue (period 2026-06-27)
- $1.02B
- Score today
- 5.1/10
Revenue source: xbrl.
How the report landed
Perrigo Company (PRGO) beat the $0.36 estimate with adjusted EPS of $0.50 — a large 40.9% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PRGO Sell at 5.1/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +40.9% surprise compares with a +20.9% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Supplier: single-source suppliers
- Target reached (-11.9% upside)
- Quality below floor (2.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $15.92
- Stop
- $14.81
Model outputs from TrendMatrix’s engine as of 2026-10-29 — shown for context, not personalized investment advice.
PRGO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $2.21B
- P/E (fwd)
- 6.7
- 52-week range
- $9.23–$21.74
- Off 52-week high
- 26.8%
- RSI (14)
- 66
- Volume vs avg
- 0.72×
- Score today
- 5.1/10